metabolic profiling of Parkinson's disease and mild cognitive impairment.
metabolic profiling of Parkinson's disease and mild cognitive impairment.
复制标题
DOI：
10.1002/mds.26992
复制
发表时间：
2017-06
期刊：
影响因子：
--
通讯作者：
Hudson G
中科院分区：
文献类型：
--
作者：
Burté F;Houghton D;Lowes H;Pyle A;Nesbitt S;Yarnall A;Yu-Wai-Man P;Burn DJ;Santibanez-Koref M;Hudson G
背景：早期诊断帕金森病和轻度认知障碍对于及时治疗和改善患者福利非常重要，但目前尚无标准的诊断测试。代谢组学是一种强大的工具，用于阐明疾病机制和识别潜在的生物标志物。目的：本研究的目的是利用代谢谱分析来了解帕金森病的病理学，并识别潜在的疾病生物标志物。方法：本研究使用已建立的基于阵列的检测系统（DiscoveryHD4™，Metabolon， UK）比较了早期帕金森患者（诊断< 12个月）与无症状匹配的对照组的血清学代谢组学特征，将代谢物水平与认知障碍的临床测量相关联。结果：在早期帕金森病患者（n = 41）和无症状对照（n = 40）中，共评估了1434种血清学代谢物。质量控制后，统计分析鉴定出n = 20种代谢物，主要是脂肪酸氧化途径的代谢物，与帕金森病和轻度认知障碍相关。受试者操作曲线评估证实，9种脂肪酸氧化代谢物对早期帕金森病和轻度认知障碍（曲线下面积= 0.759）具有良好的预测准确性（曲线下面积= 0.857）。结论：我们的研究表明，脂肪酸氧化可能是帕金森病病理生理的一个重要组成部分，可能有潜力作为疾病发病和轻度认知障碍的诊断生物标志物。©2017作者。Wiley期刊公司代表国际帕金森和运动障碍学会出版的《运动障碍》。
Background: Early diagnosis of Parkinson's disease and mild cognitive impairment is important to enable prompt treatment and improve patient welfare, yet no standard diagnostic test is available. Metabolomics is a powerful tool used to elucidate disease mechanisms and identify potential biomarkers. Objectives: The objective of this study was to use metabolic profiling to understand the pathoetiology of Parkinson's disease and to identify potential disease biomarkers. Methods: This study compared the serological metabolomic profiles of early‐stage Parkinson's patients (diagnosed < 12 months) to asymptomatic matched controls using an established array based detection system (DiscoveryHD4™, Metabolon, UK), correlating metabolite levels to clinical measurements of cognitive impairment. Results: A total of 1434 serological metabolites were assessed in early‐stage Parkinson's disease cases (n = 41) and asymptomatic matched controls (n = 40). Post–quality control, statistical analysis identified n = 20 metabolites, predominantly metabolites of the fatty acid oxidation pathway, associated with Parkinson's disease and mild cognitive impairment. Receiver operator curve assessment confirmed that the nine fatty acid oxidation metabolites had good predictive accuracy (area under curve = 0.857) for early‐stage Parkinson's disease and mild cognitive impairment (area under curve = 0.759). Conclusions: Our study indicates that fatty acid oxidation may be an important component in the pathophysiology of Parkinson's disease and may have potential as a diagnostic biomarker for disease onset and mild cognitive impairment. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.